Search for contacts, projects,
courses and publications

Breakthrough genetic breast cancer trial: a randomised phase II pilot trial of docetaxel versus carboplatin for patients with relapsed genetic breast cancer

People

Leaders

Schulz P. J.

(Responsible)

Collaborators

Rubinelli S.

(Coordinator)

Vago F.

(Collaborator)

Abstract

The project developed communication strategies for a randomized trial for the treatment of relapsed genetic breast cancer. The HCC Lab, in collaboration with the TEC (Technology Enhanced Communication) Lab of the University of Lugano, was responsible for the development of a website for the recruitment of about 150 European patients to be involved in the trial. The website applied communication strategies, such as a content intensive website, virtual meetings in 3D and discussion forums in order to support patients¿ decision to provide "informed consent" for the trial. We were attempting to minimize the need for face to face encounters between health professionals and patients during the recruitment phase, as well as assisting patients during their actual participation in the trial.

Additional information

Start date
01.01.2005
End date
01.06.2006
Duration
17 Months
Status
Ended
Research areas
S265 Press and communication sciences
S290 Social medecine